Increased premiums and less help for insurance companies will make 2017 quite a different year for Obamacare, analyst Ipsita Smolinksi says.
ST. LOUIS— Express Scripts Holding Co. on Tuesday reported third-quarter profit of $722.9 million. Eleven analysts surveyed by Zacks expected $25.56 billion. Companies like Express Scripts run prescription drug coverage for insurers, large employers and other customers.
CNBC's Meg Tirrell reports the latest news in pharma, including Novartis under pressure, and Merck's FDA drug approval.
Jim Chanos, Kynikos Associates President and founder, explains why he is short Valeant Pharmaceuticals.
DUBLIN, Oct 25- Ireland's government on Tuesday put forward Dublin as the latest potential new home of the European Medicines Agency should the organisation uproot from London after Britain's vote to leave the European Union. Cities around Europe, including Spain, France, Sweden, Poland, Italy and Austria, are racing to entice one or other organisation in the...
Merck reported a 19.6 percent rise in net profit, driven primarily by higher demand for its new cancer drug Keytruda.
Mylan has raised prices of the anti-allergy device more than 500 percent in recent years.
Eli Lilly reported third-quarter revenue below Wall Street estimates, driven by lower demand for its products outside the United States.
John Lechleiter, Eli Lilly CEO, breaks down the company's quarterly results which reported EPS of $0.88 (adj.) on revenues of $5.19 billion.
INDIANAPOLIS— Eli Lilly's profit slipped 3 percent in the third quarter and the drugmaker fell well short of Wall Street expectations as competition and a loss of patent protection chopped revenue for some key products. The company expects adjusted earnings of between $3.50 and $3.60 per share on revenue ranging from $20.8 billion to $21.2 billion.
Oct 25- Eli Lilly and Co reported a 4.7 percent jump in quarterly revenue, fueled by demand for its newer drugs. The Indianapolis- based drugmaker said its net income fell to $778 million, or 73 cents per share, in the third-quarter ended Sept. 30, from $799.7 million, or 75 cents per share, a year earlier. Revenue rose to $5.19 billion from $4.96 billion.
FRANKFURT, Germany— Swiss drug company Novartis saw net profit slip in the third quarter as the loss of a key drug to generic use in the United States outweighed strong sales of its psoriasis drug Cosentyx and MS treatment Gilenya. Core net income fell 2 percent to $2.94 billion from $2.99 billion in the previous-year quarter. Gilenya, a medicine for relapsing...
Bill Miller, LMM Investments, shares his take on Valeant and energy stocks.
*Spain outperforms as political deadlock seen ending. MILAN/ LONDON, Oct 24 (Reuters)- European shares ended flat on Monday with continued gains in banks offset by weakness among pharma stocks, while Spain outperformed on signs of an end to a political deadlock. The STOXX 600 Bank index rose 1.4 percent, making gains for the fifth session in a row and erasing all of its...
*Consensus forecasts point to $1.05 billion sales in 2021. LONDON, Oct 24- GlaxoSmithKline has filed its shingles vaccine Shingrix for U.S. regulatory approval, the drugmaker said on Monday, bringing the potential $1 billion- a-year seller a step closer to market. The company, which will see Emma Walmsley take over as chief executive in 2017, is seeking to...
TOKYO, Oct 24- Japanese stocks edged up in thin trade on Monday after investors bought drugmakers on hopes for strong mid-year earnings, offseting weakness in such cyclical stocks as exporters which languished on profit-taking. The Nikkei gained 0.3 percent to 17,234.42 in choppy trade. Turnover was 1.566 trillion yen, the lowest since May 30.
TOKYO, Oct 24- Japan's Nikkei share average was flat in choppy trade on Monday morning after profit-taking in cyclical stocks offset gains in drugmakers which had raised their earnings outlooks. "There are few investors who want to chase the market higher until they see more news from overseas especially regarding a U.S. rate hike," said Yutaka Miura, senior...
Mylan has been accused of underpaying Medicaid in rebates for EpiPens, and agreed to pay $465 million to the government to resolve such claims.
SAO PAULO, Oct 21- Bain Capital LP, Advent International Corp and Torrent Capital Investment Corp are on a shortlist of suitors for a Brazilian generic drug making joint-venture in which Pfizer Inc has a 40 percent stake, two people with direct knowledge of the situation said on Friday. The sale underscores the challenge facing generic drugmakers in Brazil,...
CNBC's Meg Tirrell reports the latest surrounding Ariad Pharmaceuticals and the company's drug price hike.